Towards a Therapeutic Reduction of Imatinib Refractory Myeloproliferative Neoplasm-Initiating Cells

Myeloproliferative neoplasms (MPNs) such as chronic myelogenous (CML) and chronic myelomonocytic leukemias (CMML) are frequently induced by tyrosine kinase oncogenes. Although these MPNs are sensitive to tyrosine kinase inhibitors such as imatinib, patients often relapse upon withdrawal of therapy....

Descripción completa

Detalles Bibliográficos
Autores principales: Philips, Steven T., Hildenbrand, Zacariah L., Oravecz-Wilson, Katherine I., Foley, S. Blake, Mgbemena, Victoria E., Ross, Theodora S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4025985/
https://www.ncbi.nlm.nih.gov/pubmed/24240679
http://dx.doi.org/10.1038/onc.2013.484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4025985/
https://www.ncbi.nlm.nih.gov/pubmed/24240679
http://dx.doi.org/10.1038/onc.2013.484

Ejemplares similares